NASH

Defining endpoints in clinical studies in NASH
Talk at the Stockholm NASH 2021 meeting, discussing trial endpoints and implications for future trial design and treatment roll out.
Last updated on Jan 13, 2022
Slides Video
Defining endpoints in clinical studies in NASH
A Systematic Review of Animal Models of NAFLD Finds High-Fat, High-Fructose Diets Most Closely Resemble Human NAFLD
Understanding the nature of animal models for NASH and their ability to recapitulate the human disease.
PDF Dataset DOI
The placebo response in randomised trials in nonalcoholic steatohepatitis simply explained
This paper describes a simple approach to understanding the placebo response to treatments for NASH.
PDF Code DOI
The placebo response in randomised trials in nonalcoholic steatohepatitis simply explained
Treatment Candidacy for Pharmacologic Therapies for NASH
This is a state of the art review of treatment candidacy for patients with NASH.
PDF DOI
Administrative Coding in Electronic Health Care Record-Based Research of NAFLD, An Expert Panel Consensus Statement
This consensus paper defines strategies to analyse administrative data in NASH.
PDF DOI
Fibrosis progression rate in a systematic review of placebo-treated nonalcoholic steatohepatitis
Using a systematic review, here we define the likely rate of fibrosis progression in NASH and its impact on the proportion of patients progressing to cirrhosis.
PDF DOI
High rates of ineligibility for participation in trials of new therapies in nonalcoholic steatohepatitis, a systematic review
This study describes the rates and causes of screen failure in large trials in NASH.
PDF DOI